186 related articles for article (PubMed ID: 38336610)
1. Nephrotic syndrome with acute kidney injury due to combination therapy of immune checkpoint inhibitors: a case report and review of the literature.
Saiki R; Katayama K; Saiki H; Fukumori A; Tsujimoto K; Yamawaki M; Tanaka F; Takahashi D; Oda K; Suzuki Y; Murata T; Dohi K
BMC Nephrol; 2024 Feb; 25(1):51. PubMed ID: 38336610
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report.
Koda R; Watanabe H; Tsuchida M; Iino N; Suzuki K; Hasegawa G; Imai N; Narita I
BMC Nephrol; 2018 Feb; 19(1):48. PubMed ID: 29486725
[TBL] [Abstract][Full Text] [Related]
3. Acute interstitial nephritis after sequential ipilumumab - nivolumab therapy of metastatic melanoma.
Bottlaender L; Breton AL; de Laforcade L; Dijoud F; Thomas L; Dalle S
J Immunother Cancer; 2017 Jul; 5(1):57. PubMed ID: 28716106
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint inhibitors associated granulomatous small vessel vasculitis accompanied with tubulointerstitial nephritis: a case report.
Tominaga K; Takeuchi K; Takakuma S; Sakamoto E; Hatanaka S; Kajimoto Y; Toda E; Terasaki Y; Kunugi S; Terasaki M; Shimizu A
BMC Nephrol; 2023 Mar; 24(1):48. PubMed ID: 36894873
[TBL] [Abstract][Full Text] [Related]
5. AKI in Patients Receiving Immune Checkpoint Inhibitors.
Perazella MA; Sprangers B
Clin J Am Soc Nephrol; 2019 Jul; 14(7):1077-1079. PubMed ID: 31048326
[No Abstract] [Full Text] [Related]
6. Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy.
Glutsch V; Grän F; Weber J; Gesierich A; Goebeler M; Schilling B
J Immunother Cancer; 2019 Jul; 7(1):181. PubMed ID: 31300044
[TBL] [Abstract][Full Text] [Related]
7. Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report.
Hultin S; Nahar K; Menzies AM; Long GV; Fernando SL; Atkinson V; Cebon J; Wong MG
BMC Nephrol; 2020 Sep; 21(1):391. PubMed ID: 32894101
[TBL] [Abstract][Full Text] [Related]
8. Acute interstitial nephritis, a potential predictor of response to immune checkpoint inhibitors in renal cell carcinoma.
Patel V; Elias R; Formella J; Schwartzman W; Christie A; Cai Q; Malladi V; Kapur P; Vazquez M; McKay R; Pedrosa I; Hannan R; Hammers H; Brugarolas J
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33139246
[TBL] [Abstract][Full Text] [Related]
9. Renal Vasculitis and Pauci-immune Glomerulonephritis Associated With Immune Checkpoint Inhibitors.
Gallan AJ; Alexander E; Reid P; Kutuby F; Chang A; Henriksen KJ
Am J Kidney Dis; 2019 Dec; 74(6):853-856. PubMed ID: 31204194
[TBL] [Abstract][Full Text] [Related]
10. Minimal change disease in a patient receiving checkpoint inhibition: Another possible manifestation of kidney autoimmunity?
Vaughan E; Connolly E; Hui M; Chadban S
Cancer Rep (Hoboken); 2020 Oct; 3(5):e1250. PubMed ID: 33085845
[TBL] [Abstract][Full Text] [Related]
11. Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report.
Miyauchi Y; Naito H; Tsunemori H; Tani R; Hasui Y; Miyake Y; Minamino T; Ishikawa R; Kushida Y; Haba R; Sugimoto M
J Med Case Rep; 2021 Oct; 15(1):508. PubMed ID: 34649593
[TBL] [Abstract][Full Text] [Related]
12. Acute tubulointerstitial nephritis and IgM deposits on glomerular capillary walls after immunotherapy with nivolumab for metastatic renal cell carcinoma.
Irifuku T; Satoh A; Tani H; Mandai K; Masaki T
CEN Case Rep; 2020 Feb; 9(1):48-54. PubMed ID: 31605271
[TBL] [Abstract][Full Text] [Related]
13. Ipilimumab/Nivolumab-related Opsoclonus-Myoclonus-Ataxia Syndrome Variant in a Patient with Malignant Pleural Mesothelioma.
Maller B; Peguero E; Tanvetyanon T
J Immunother; 2018; 41(9):411-412. PubMed ID: 29742520
[TBL] [Abstract][Full Text] [Related]
14. [INTERSTITIAL NEPHRITIS CAUSED BY IPILIMUMAB AND NIVOLUMAB COMBINATION THERAPY FOR ADVANCED RENAL CELL CARCINOMA: A CASE REPORT].
Ishii M; Takezawa K; Imamura R; Fukuhara S; Fujita K; Uemura M; Kiuchi H; Nonomura N
Nihon Hinyokika Gakkai Zasshi; 2021; 112(2):109-112. PubMed ID: 35444079
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab-associated nephrotic syndrome recovered from transient hemodialysis in a patient with lung cancer.
Ishibuchi K; Iwakura T; Kaneko M; Fukasawa H; Furuya R
CEN Case Rep; 2020 Aug; 9(3):215-219. PubMed ID: 32170578
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab plus ipilimumab induced endocrinopathy and acute interstitial nephritis in metastatic sarcomatoid renal-cell carcinoma: A case report and review of literature.
Hino C; Nishino K; Pham B; Jeon WJ; Nguyen M; Cao H
Front Immunol; 2022; 13():993622. PubMed ID: 36052087
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab and Ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation.
Valenti-Azcarate R; Esparragosa Vazquez I; Toledano Illan C; Idoate Gastearena MA; Gállego Pérez-Larraya J
Neuromuscul Disord; 2020 Jan; 30(1):67-69. PubMed ID: 31839404
[TBL] [Abstract][Full Text] [Related]
18. Is Rechallenge Appropriate in Patients that Develop Immune Checkpoint Inhibitor-Associated AKI?: CON.
Kanduri SR; Velez JCQ
Kidney360; 2022 May; 3(5):803-805. PubMed ID: 36128485
[No Abstract] [Full Text] [Related]
19. Case Report: A Variety of Immune-Related Adverse Events Triggered by Immune Checkpoint Inhibitors in a Subject With Malignant Melanoma: Destructive Thyroiditis, Aseptic Meningitis and Isolated ACTH Deficiency.
Katakura Y; Kimura T; Kusano T; Tatsumi F; Iwamoto Y; Sanada J; Fushimi Y; Shimoda M; Kohara K; Nakanishi S; Kaku K; Mune T; Kaneto H
Front Endocrinol (Lausanne); 2021; 12():722586. PubMed ID: 34712202
[TBL] [Abstract][Full Text] [Related]
20. Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes.
Meraz-Muñoz A; Amir E; Ng P; Avila-Casado C; Ragobar C; Chan C; Kim J; Wald R; Kitchlu A
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32601079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
